Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Clene (CLNN)
NASDAQ:CLNN
Clene (CLNN) Stock Price & Analysis
811 Followers
CLNN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.25 - $1.09
Previous Close$0.42
Volume313.02K
Average Volume (3M)961.31K
Market Cap
$54.40M
Enterprise Value$46.31M
Total Cash (Recent Filing)$35.00M
Total Debt (Recent Filing)$26.90M
Price to Earnings (P/E)-0.8
Beta0.02
Next Earnings
Aug 12, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding128,430,098
10 Day Avg. Volume562,217
30 Day Avg. Volume961,312
Standard Deviation0.30
R-Squared0.02
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)4.17
Price to Sales (P/S)83.19
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue81.53
Enterprise Value/Gross Profit86.88
Enterprise Value/Ebitda-1.11
Forecast
1Y Price Target
$4.33Price Target Upside1006.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Clene News
PremiumPre-Earnings
Is CLNN a Buy, Before Earnings?
PremiumCompany Announcements
Clene Announces Breakthrough MS Therapy at Neurology Meeting
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Drug EfficacyStudy participants treated with CNM-Au8 experienced significant improvements in visual amplitude and latency, suggesting enhanced neuronal health and remyelination.
Financial StabilityWith $35 million in cash reserves at year-end, the company is well-financed to sustain ongoing operations and continue its clinical development programs.
Regulatory MilestonesAnalysts expect the FDA to accept CNM-Au8's New Drug Application filing, potentially positioning it as a strong contender in the ALS therapy market.
Bears Say
Clinical Trial OutcomesNo statistically significant differences in the primary endpoint of ALSFRS-R score change from baseline vs. placebo.
EarningsFinancial results posted EPS of ($0.08) and ($0.47), respectively, missing both the company's estimates and consensus.
Regulatory ApprovalInitial findings on plasma neurofilament light chain (NfL) reductions were insufficient to support accelerated approval.
---
Ownership Overview
37.22% Insiders
2.75% Mutual Funds
2.64% Other Institutional Investors
57.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLNN FAQ
What was Clene’s price range in the past 12 months?
Clene lowest stock price was $0.25 and its highest was $1.09 in the past 12 months.
What is Clene’s market cap?
Currently, no data Available
When is Clene’s upcoming earnings report date?
Clene’s upcoming earnings report date is Aug 12, 2024 which is in 95 days.
How were Clene’s earnings last quarter?
Currently, no data Available
Is Clene overvalued?
According to Wall Street analysts Clene’s price is currently Undervalued.
Does Clene pay dividends?
Clene does not currently pay dividends.
What is Clene’s EPS estimate?
Clene’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clene have?
Clene has 128,433,720 shares outstanding.
What happened to Clene’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Clene?
Currently, no hedge funds are holding shares in CLNN
---
Clene Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.33 (1006.29% Upside)
$4.33 (1006.29% Upside)
Blogger Sentiment
Bullish
CLNN Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $11.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.00%
12-Months-Change
Fundamentals
Return on Equity
-595.47%
Trailing 12-Months
Asset Growth
17.64%
Trailing 12-Months
Company Description
Clene
Clene is a clinical-stage biopharma company focused on developing and commercializing nanotherapeutics for the treatment of neurodegenerative disease.
---
CLNN Stock 12 Month Forecast
Average Price Target
$4.33
▲(1006.29% Upside)
Technical Analysis
Cellectar Biosciences
―
ACADIA Pharmaceuticals
―
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Best Analysts Covering CLNN
1 Year
1 Year Success Rate
4/15 ratings generated profit
1 Year Average Return
-26.96%
reiterated a buy rating 22 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 26.67% of your transactions generating a profit, with an average return of -26.96% per trade.
---